EKF highlighting expanding range of liquid stable clinical chemistry reagents at Hospitalar

New diabetes and sepsis biomarkers introduced to South America
at Stand K77, Hospitalar 2015, Sao Paulo, Brazil

EKF Diagnostics, the global diagnostics company, will be highlighting its expanding Stanbio central laboratory clinical chemistry range at Hospitalar, 19–22 May, Sao Paulo, Brazil.  This range includes a large selection of clinical chemistry assays, controls and calibrators, which are fully compatible with most major brand open channel chemistry analyzers.

On Stand K77, EKF will discuss new additions to its Stanbio range of liquid-stable clinical chemistry reagents (Liquicolor® and Liqui-UV®) which are designed for maximum stability and ease of use. These include a new diabetes biomarker test that provides a 2-3 week indicator of average blood glucose - the Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test as well as the new Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay for early sepsis identification.

EKF’s Stanbio Chemistry Glycated Serum Protein (GSO) LiquiColor® test

EKF will also be showcasing its wide range of point-of-care (POC) hematology analyzers. These deliver quick and laboratory accurate results to aid diagnoses of anemia and associated conditions within a variety of near-patient settings, including hospitals, clinics, blood banks and in challenging field-based conditions.

EKF will demonstrate its portfolio of easy-to-use and reliable hemoglobin/hematocrit analyzers designed to meet a range of POC testing needs. These include the UltraCrit Plus™ which is a high accuracy hematocrit (Hct) measurement device for blood donor screening. Using reagent-less cuvettes to obtain a result from a single drop of blood within 30 seconds, its accuracy of ≤0.4% Hct, has been shown to decrease both “false deferrals” and “false accepts”. UltraCrit Plus™ is the first and only hematocrit/hemoglobin device to use ultrasound technology, which enables high accuracy results with an imprecision of <0.8%.

Other EKF hemoglobin analyzers to be demonstrated include HemoPoint H2 and DiaSpect Tm. A hand held device delivering results in <2 seconds, DiaSpect Tm is the world’s fastest hemoglobin measurement system offering laboratory quality performance for anemia screening in all climatic conditions. Storing over 4000 patient results, the HemoPoint H2 is designed for use in blood banks, clinics and hospitals and provides immediate lab-quality results for both hemoglobin and hematocrit from one test. Its proprietary “soft load” cuvette holder is designed to minimize contamination of the meter.

For more information on EKF Diagnostics and its range of hematology products, please visit www.ekfdiagnostics.com .

About EKF Diagnostics - www.ekfdiagnostics.com  
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc., DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology.  EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.

Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.

Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.

Molecular Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics following the acquisition of UK-based 360 Genomics. EKF Molecular Diagnostics’ technology, PointMan™, is capable of detecting mutant genes from tiny biopsy and blood samples and has recently entered a partnership with the world renowned cancer research center at Massachusetts General Hospital, USA.

EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.